No Data
Raygene (688217.SH): The company did not repurchase shares in October.
On November 4, Ruian Genetics (688217.SH) announced that in October 2024, the company did not repurchase any shares. As of October 31, 2024, the company has cumulatively repurchased 669,621 shares of the company through the Shanghai Stock Exchange trading system in a centralized bidding trading method, accounting for 1.20% of the company's total share capital of 55,855,896 shares. The highest repurchase price was RMB 27.67 per share, the lowest price was RMB 22.37 per share, and the total amount paid was RMB 17,021,747.99 (excluding stamp duty, transaction commission, and other transaction fees).
What exactly happened to the four senior executives of Raytheon Gene who were detained?
Market speculation may be related to the AstraZeneca insurance fraud case. There are new developments in the forced measures taken by high-level executives of Ruian Gene mentioned in Investor Network. On October 25, Ruian Gene announced that the families of four high-level executives, Ms. Xiong Hui, Mr. Xiong Jun, Mr. Xue Yuwei, and Mr. He Junyan, have had their forced measures changed to criminal detention, and the suspected charges changed to fraud. Further investigation is still pending. Earlier in July, Ruian Gene announced that the company's controlling shareholder, director, and general manager Ms. Xiong Hui, controlling shareholder, director, and vice general manager Mr. Xiong Jun, as well as vice general manager Mr. Xue Yuwei, were suspected of illegal operation and were taken by the public security authorities.
Rayon Genomics 2024 Third Quarter Report
A-share abnormal movement | Four executives were detained, Ruiang Genes once fell sharply by 13% during trading hours.
On October 28th, Ray X Genetic (688217.SH) once plummeted by 13% in mid-trading, now at 18.5 yuan, narrowing its decline to 5.4%, with a market cap perilously close to 1 billion yuan. The company announced last Friday night that four senior executives, including the director, were formally detained for alleged fraud. For Ray X Genetic, which just landed on the STAR Market more than three years ago, this is undoubtedly a bolt from the blue, with half of the core management team 'going in'. Market rumors suggest that the collective trouble of Ray X Genetic's senior executives may be related to Astrazeneca's insurance fraud case. (格隆汇)
RayonGene's senior management is suspected of changing the charges to fraud, and Astrazeneca was once its main client.
Reangene was established in 2012 and is a genetic testing company focusing on the field of oncology.
Express News | Ruiang Gene: The company executives' mandatory measures have been changed to criminal detention, and the suspected charges have been changed to fraud.
No Data
No Data